Mitigating Data Overload by Moving to Proactive Pharmacovigilance

Utilizing pharmacovigilance data in real time can improve patient outcomes by identifying potential drug-drug or drug-disease interactions, AE trends, or benefits not realized in clinical trials.

For example, when it comes to the COVID-19 pandemic, comparative data, along with other PV data, can be used to determine if existing drugs are beneficial to – or pose additional risks in – patients who become ill with the disease.

But despite technological advances supporting pharmacovigilance, not changing the way of working with PV data leaves most struggling to obtain a deep understanding of it.

This perspective, authored by Kari Blaho-Owens, Ph.D, director of pharmacovigilance and safety at Perficient, outlines the history of pharmacovigilance, current challenges and ROI opportunities, and how to remain proactive in the future.